allogeneic CD3- CD19- selected natural killer cells

{
  "id": "MLC-T-ONC-009852",
  "term": "allogeneic CD3- CD19- selected natural killer cells",
  "field": "Oncology and biomedicine",
  "definition": "Human leukocyte antigen (HLA)-haploidentical donor-derived natural killer (NK) cells that are activated with the cytokine interleukin-15 (IL-15), with immunomodulating and antineoplastic activities. Upon leukapheresis, the HLA-haploidentical donor peripheral blood mononuclear cells (PBMCs) are treated to remove T lymphocytes (CD3+) and B-lymphocytes (CD19+) cells. In turn, NK cells are expanded and activated with IL-15. Upon infusion of the allogeneic CD3- CD19- selected NK cells, these cells recognize and bind to tumor cells, and secrete perforins, granzymes, and cytokines, which results in cancer cell lysis.",
  "synonyms": [
    "allogeneic CD3-/CD19- NK cell product",
    "allogeneic CD3-/CD19- NK cells",
    "allogeneic CD3-/CD19- natural killer cells",
    "CD3/CD19-depleted donor NK cells"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/allogeneic-cd3-cd19-selected-natural-killer-cells/"
}